Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AstraZeneca divests rights to established hypertension medicines

27 January 2020 07:00 GMT AstraZeneca divests rights to established hypertension medicines Sale of Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharmasupports AstraZeneca's strategy of focusing on pipeline of new medicines AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs). The agreement excludes the rights in the US and India,

Brilinta met primary endpoint in Phase III THALES trial in stroke

27 January 2020 07:00 GMT Brilinta met primary endpoint in Phase III THALES trial in stroke Brilinta reduced the risk of the composite of stroke and deathafter an acute ischaemic stroke or transient ischaemic attack High-level results from the Phase III THALES trial showed AstraZeneca's Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone. THALES was conducted in over 11,000 patients who

AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan

27 January 07.00 GMT   AstraZeneca to recover the global rights tobrazikumab (MEDI2070) from Allergan Agreement strengthens AstraZeneca's respiratory and immunology pipeline AstraZeneca will recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III programme in Crohn's disease (CD)[1] and a Phase IIb trial in ulcerative colitis (UC).[2] AstraZeneca and Allergan will terminate their existing license agreement 

Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint

27 January 2020 07:00 GMT   Phase II DESTINY-Gastric01 trial of Enhertu versuschemotherapy met primary endpoint Trial met primary endpoint of objective response rate and key secondaryendpoint of overall survival in patients with previously treated HER2-positive metastatic gastric cancer High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca's and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan), achieved a statistically significant and clinically meaningful improvement in objective response

Wihlborgs signs leases in Prisma, Helsingborg

Wihlborgs has signed two new leases at the Prisma office building, currently being constructed in the Oceanhamnen area of Helsingborg. On 1 January 2021, Assistansbolaget Försäkring Sverige AB and KPMG will move in to the building.Assistansbolaget will be occupying 600 m² on the top floor of Prisma. The company’s office is currently in smaller premises on the top floor of Terminalen 1, above Helsingborg Central Station.  “Being able to offer its employees Helsingborg’s hands-down best work environment – a combination of functionality, comfort and connection to public transportation – is

Hansa Biopharma completes enrollment in anti-GBM

The completion of enrollment in the anti-GBM study marks an important milestone for the Company’s expansion outside transplantation. Anti-GBM is a rare immunological disease with a significant unmet medical need.Lund, Sweden January 27, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases today announced that the patient enrollment in an investigator-initiated phase 2 study to evaluate safety, tolerability and efficacy of imlifidase in 15 patients with severe Anti-GBM antibody disease has now been completed. A first data read out is expected

Share buy-backs in Telia Company during week 4 2020

During the period January 20, 2020 until January 24, 2020, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 2,621,708 own shares (ISIN: SE0000667925).The share buy-backs form part of the SEK 5 billion share buy-back program that Telia Company announced on April 16, 2019. The share buy-back program, which runs between April 16, 2019 and February 28, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period

Axactor expands relationship with FI Client in Norway

Oslo, January 27th 2020 Axactor has renewed and expanded an existing FF, acquiring fresh NPL consumer finance claims, with an outstanding balance of less than €25k. The new contract period is for 12 months, starting in February 2020, with an expected annual capex of around 10mEUR. The contract includes a hybrid element with part of the FF being managed in 3PC for a period prior to acquisition.  “Axactor Norway is happy to announce this renewal, which has been developed to include not only additional volumes, but also a hybrid element including 3PC. The team have been working hard to

Online brokerage customers from S-Banken to Nordnet

S-Banken and Nordnet have agreed on a cooperation whereby S-Banken’s online securities brokerage customer base in Finland moves to Nordnet. Customers from S-Banken will start investing through Nordnet’s platform in April 2020.-   Nordnet is one of the strongest brands in Finland within savings and investments, and through this co-operation we will strengthen our position even further. I would like to say a warm welcome to the new customers from S-Banken. Our whole team will do it’s best to give them excellent service from day one, says Lars-Åke Norling, CEO at Nordnet. S-Banken provides

Changed accounting period for previously communicated divestment of development projects

Catella AB (publ) communicated via a press release on October 2, 2019 that, through its associated company Nordic Seeding GmbH, the Company has signed an agreement with the German property developer CG Gruppe AG to divest the Grand Central property development project in Düsseldorf, Germany. The transaction has a total positive effect on the profit after tax of approximately SEK 170 M, which is expected to be reported during the first quarter of 2020. The transaction was previously communicated to be reported during the fourth quarter of 2019. The transaction and value for Catella are

YIT started construction of two new apartment buildings in Russia in October–December

YIT Corporation Press release January 27, 2020 at 7:00 a.m.In October–December 2019, YIT started construction of two new apartment buildings in Russia. The projects are located in Yekaterinburg and Tyumen. The total value of the projects is approximately EUR 22 million, with nearly 500 apartments to be completed. The start-ups of the apartments are booked in the order backlog of the fourth quarter of 2019. In Yekaterinburg, YIT started the construction of a new apartment building called Vektori. The 25-storey building will feature more than 270 apartments and a parking hall with business

P-O Westerlund appointed new CEO

The board of directors has appointed P-O Westerlund CEO of Nepa AB (publ). The appointment is effective immediately.   Chairman of the Board, Ulrich Boyer commented: ”The company needs transformation and change. It needs a sales strategy aimed at a more focused offer to unlock the potential in our core offering and our underlying technical platform.  We also need a clear focus on sound finances through cost control, efficiency and risk management. In P-O Westerlund we have a skilled leader to deliver what we need, now.”  P-O Westerlund, Nepa’s new CEO commented: ”I look forward to

New Player Enters the Swedish Investment Scene

Aldeon to focus on early stage founders within games & techStockholm (Jan 26, 2020) - Spearheaded by industry and entreprenural veterans Daniel Laurén, Susana Meza Graham, and Andras Vajlok, Aldeon is a newly formed independent investment company focused on working with games and tech start-ups in their early stages. The new initiative currently has 20 holdings, acquired by its three founders over a number of years.  Aldeon's focus will primarily be on local entrepreneurs in the Nordics as the founders believe there is strength in proximity combined with the incredible hotbed of talent

Strong development for Hudya

- Strong sales development, lower costs for customer acquisition and intent agreement with Optin BankThe fintech company Hudya - which carries out a new share issue and listing process at the Nasdaq First North Growth Market - has had a strong development, both in terms of sales and ever-lower costs for customer acquisition. In addition, Hudya has signed an important letter of intent with Optin Bank regarding payment solutions. - We are very pleased with how sales are developing and that we have low costs for our customer acquisition. An important part of our strong sales development is

Oncopeptides will host a webcast on Monday, January 27[th] at 11.00 (CET)

STOCKHOLM — January 24, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that it will host a webcast at 11am (CET) on Monday, January 27[th] 2020 where CEO Jakob Lindberg will present and explain melflufen’s mechanism of action.Conference call for investors, analysts and the media, Monday, January 27[th] 2020, at 11 (CET). Phone numbers for participants from: Sweden: +46 8 505 58 352Europe: +44 3333 009 262USA: +1 833 526 8347 The conference call will also be streamed on the corporate website www.oncopeptides.com and via the link below. https://tv.

Prestigious sustainability award to Xavi and Genexis

Genexis, the product company of Inteno Group, and its ODM partner Xavi have recieved the prestigious JAC sustainability and CSR certification. The Joint Audit Cooperation (JAC, jac-initiative.com) is a collective of 17 telecommunication companies, including Telia, Telenor, KPN, Elisa, AT&T, Deutsche Telekom and Vodafone. The purpose is to promote safe and fair working conditions as well as responsible, social and environmental management by verifying, assessing and promoting sustainability standards and transfer of best practice across the supply chain. “We are proud to receive

Correction Statement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. THIS PUBLICATION IS NEITHER AN OFFER TO BUY OR SELL NOR AN INVITATION TO TENDER OR OFFER TO BUY OR SELL SHARES.   Read the whole press release here .   About RecipharmRecipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 7,000 employees. Recipharm offers manufacturing

Adapteo Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act

Adapteo Plc Regulatory press release 24 January 2020 at 17:00 p.m. CET Adapteo Plc (the “Company”) has on 23 January 2020 received a notification pursuant to Chapter 9, Section 5 of the Securities Markets Act from Nordea Funds Ltd. According to the notification, the holding of Nordea Funds Ltd in the Company’s shares and votes has fallen below 5 per cent on 22 January 2020. Nordea Funds Ltd holds a total of 2,171,702 shares and 2,224,910 voting rights corresponding to an ownership of 4.86 percent in Adapteo’s shares and 4.98 percent in votes. Adapteo has a total of 44,682,697

NOTICE OF EXTRAORDINARY GENERAL MEETING AT SCANDINAVIAN ENVIRO SYSTEMS AB (publ)

Shareholders of Scandinavian Enviro Systems AB (publ) (the Company), co. reg. no. 556605-6726, are hereby invited to an Extraordinary General Meeting on Thursday, February 27, 2020 at 16:00 at Hotel Kusten, Kustgatan 10, SE 414 55 Gothenburg, Sweden. Registration for the meeting will commence at 15:30.N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. NOTIFICATIONShareholders who wish to attend the meeting must: i. be entered in the share register

#20-26 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

#20-25 Delisting of certain derivatives from NGM

Certain derivatives will be delisted from NGM.For more details see attached files. For further information concerning this NGM notice please contact: Listing department on +46 8 566 390 20 or at listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Comment to the founders’ sale of shares

The two founders of ODI Pharma AB (“ODI” or “Company”), Derek Simmross and Volker Wiederrich, yesterday sold a part of their respective holdings in the Company. The total sale amounts to 251,166 shares. The founders’ holdings prior to the IPO remains, and the founders have no intention to sell more than what has already been sold.Derek Simmross, CEO, and Volker Wiederrich, Chairman of the Board, comment “We have understood that the share sale we made yesterday has caused some concern. We want to clarify the reasons behind the sale, which are personal financial reasons as we have not, and

Invitation - DNB's fourth quarter results for 2019 will be presented on Thursday 6 February

DNB will publish its results for the fourth quarter of 2019 on Thursday 6 February 2020 at 7.30 a.m. CET. Thursday 6 February at 9:30 am CET: press conference in English accessible via live web TVPlace: DNB's head office in Bjørvika, Dronning Eufemias gate 30, Oslo. A live broadcast will be available on the Investor Relations pages at ir.dnb.no.Please register your attendance in Oslo by email to ca@dnb.no. Thursday 6 February at 1:30 pm CET: conference call for analysts and investorsTo attend the conference call: (+47) 21 56 33 18, or International line: (+44) (0) 20 30 03 26 66.

Inhalation Sciences signs CRO contract worth 750 KSEK with global corporation based in Europe

(Stockholm 24 January, 2020) Inhalation Sciences (ISAB) has signed a CRO (Contract research) order worth 750 KSEK with a returning customer who has carried out extensive previous CRO with ISAB, and purchased ISAB lab systems.The total value of the order is 1.1 MSEK. 750 KSEK is for services provided by ISAB, and the remaining 350 KSEK to other research companies collaborating on the project. This CRO will employ ISAB’s novel in vitro simulation tool DissolvIt, and its IPL (Isolated Perfuse Lung) module. ISAB CEO Manoush Masarrat “When clients of this calibre return time and again, it

There are no items matching the current filter
There are no more items matching the current filter
Back to top